Slingshot Insights

Catalyst

Slingshot members are tracking this event:

International Phase 3 Study Results of RLX030 (seralaxin) for Acute Heart Failure Due 2016

Source Link:: http://phx.corporate-ir.net/phoenix.zhtml?c=123046&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEwNzgzMTUxJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

ENDP

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details Update on March 2 2017: This study has been completed.

https://clinicaltria...

Additional Relevant Details A second ongoing Phase III study follows a request from Canadian regulators for more evidence of the therapy’s efficacy, with results expected by 2017. Regulatory applications were filed based on Phase II and III studies suggesting RLX030 helped patients with acute heart failure live longer.

http://phx.corporate...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Mar 02, 2017

Occurred Source:

https://clinicaltrials.gov/archive/NCT01870778/2017_03_02/changes

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Data, Rlx030, Seralaxin, Acute Heart Failure